New Partnership Introduces Advanced Drug Residue Detection Technology to Canadian Market

A strategic partnership between Taizhou Kaimi Biotech and Scenesafe Trauma Scene Remediation will introduce the Unow™ Drug Residue Test Device to the Canadian market, promising enhanced capabilities for detecting trace amounts of hazardous substances. The innovative portable testing solution enables swift, laboratory-grade identification of dangerous drugs including opioids, fentanyl, and methamphetamine. This technology addresses critical safety concerns across multiple sectors by providing rapid on-site testing capabilities that were previously unavailable in portable formats.

The Unow™ device is designed to serve law enforcement investigations by enabling immediate drug residue detection at crime scenes and during evidence collection. For healthcare facilities, the technology ensures sterile environments by verifying the absence of drug contamination in treatment areas and patient rooms. Remediation teams can use the device to validate decontamination efforts following drug-related incidents, while residential and commercial property owners can employ it to safeguard their spaces against hidden contamination risks.

Otis Zhao, President and Founder of Taizhou Kaimi Biotech, emphasized the technology's potential to protect communities, noting that the partnership with Scenesafe ensures the solution meets specific Canadian market requirements. The collaboration combines Taizhou Kaimi Biotech's biotech innovation expertise with Scenesafe's comprehensive understanding of Canadian safety protocols, aiming to establish a new standard in drug residue detection and remediation practices.

Hang Ai, Founder of Scenesafe, highlighted the device's significance in addressing drug contamination risks for first responders, families, and businesses. The portable nature of the Unow™ device allows for immediate testing in various environments without the need for laboratory analysis, potentially reducing exposure risks and speeding up safety verification processes. This capability is particularly important for emergency responders who frequently encounter unknown substances during their work.

The Unow™ Drug Residue Test Device is scheduled for availability to Canadian clients in the second quarter of 2025, with pre-orders anticipated to open soon. This strategic partnership represents a significant advancement in portable diagnostic technologies and public safety solutions, potentially transforming how drug contamination is detected and managed across multiple Canadian industries and community settings.